Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene

被引:133
作者
Schuffenecker, I
Virally-Monod, M
Brohet, R
Goldgar, D
Conte-Devolx, C
Leclerc, L
Chabre, O
Boneu, A
Caron, J
Houdent, C
Modigliani, E
Rohmer, V
Schlumberger, M
Eng, C
Guillausseau, PJ
Lenoir, GM
机构
[1] Univ Lyon 1, CNRS UMR 5641, F-69373 Lyon 08, France
[2] Hop Edouard Herriot, Genet Lab, Lyon, France
[3] Hop Lariboisiere, Serv Med Interne, F-75475 Paris, France
[4] Ctr Int Rech Canc, Lyon, France
[5] CHU Marseille, Serv Endocrinol, Marseille, France
[6] CHU Lille, Serv Endocrinol, F-59037 Lille, France
[7] CHU Grenoble, Serv Endocrinol, F-38043 Grenoble, France
[8] Ctr Claudius Regaud, Toulouse, France
[9] CHU Reims, Serv Med Interne, Reims, France
[10] CHU Rouen, Serv Endocrinol, Rouen, France
[11] Hop Avicenne, Serv Endocrinol, F-93009 Bobigny, France
[12] CHU Angers, Angers, France
[13] Harvard Univ, Sch Med, Dana Farber Canc Inst, Human Canc Genet Unit, Boston, MA 02115 USA
[14] CHU Marseille, Serv Endocrinol, Marseille, France
关键词
D O I
10.1210/jc.83.2.487
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Germline mutations of the RET proto-oncogene are responsible for multiple endocrine neoplasia type 2, including multiple endocrine type 2A (MEN 2A), type 2B (MEN 2B), and familial medullary thyroid carcinoma. The relationship between specific mutations and syndromic features has been established. In particular, the risk for pheochromocytoma and hyperparathyroidism (HPT) in MEN 2A patients is clearly associated with the presence of the RET mutation at a specific position, i.e. at codon 634. Also, a correlation between a specific mutation, C634R, and the development of HPT has been suggested but is still controversial. To further investigate the relationship between specific mutations of codon 634 and the development of HPT, we studied a population of 188 individuals, carrying mutations at codon 634, namely C634R (65 patients belonging to 10 families), C634Y (80 patients belonging to 11 families), or the less frequent codon 634 mutations [i.e. C634S, C634F, C634G, or C634W (43 patients belonging to 9 families)]. In this series of patients, we defined an overall HPT prevalence of 19.1% and found that this prevalence did not vary significantly, with respect to the nature of the mutation. However, irrespective of the particular mutation, the prevalence of HPT showed a high interfamilial variability. The statistical model that best fitted with the observed data was in favor of the heterogeneity of the risk for HPT, with 40% of the families showing an HPT risk of 34% and 60% of the families showing an HPT risk of 9%. In addition, our study clearly demonstrated that HPT could he an early component of the disease and provided the first estimate of age-specific and mutation-specific HPT penetrance in individuals with mutations of codon 634 of the RET proto-oncogene.
引用
收藏
页码:487 / 491
页数:5
相关论文
共 32 条
[1]  
ASAI N, 1995, MOL CELL BIOL, V15, P1613
[2]  
BOLINO A, 1995, ONCOGENE, V10, P2415
[3]  
Borrello MG, 1995, ONCOGENE, V11, P2419
[4]   SINGLE MISSENSE MUTATION IN THE TYROSINE KINASE CATALYTIC DOMAIN OF THE RET PROTOONCOGENE IS ASSOCIATED WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B [J].
CARLSON, KM ;
DOU, SS ;
CHI, D ;
SCAVARDA, N ;
TOSHIMA, K ;
JACKSON, CE ;
WELLS, SA ;
GOODFELLOW, PJ ;
DONISKELLER, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (04) :1579-1583
[5]   Multiple endocrine neoplasia type 2: Management of patients and subjects at risk [J].
ConteDevolx, B ;
Schuffenecker, I ;
Niccoli, P ;
Maes, B ;
Boneu, A ;
Barbot, N ;
Corcuff, JB ;
Murat, A ;
Henry, JF ;
Modigliani, E .
HORMONE RESEARCH, 1997, 47 (4-6) :221-226
[6]  
DONOVAN DT, 1990, THYROID DISEASE ENDO, P501
[7]   GDNF signalling through the Ret receptor tyrosine kinase [J].
Durbec, P ;
MarcosGutierrez, CV ;
Kilkenny, C ;
Grigoriou, M ;
Wartiovaara, K ;
Suvanto, P ;
Smith, D ;
Ponder, B ;
Costantini, F ;
Saarma, M ;
Sariola, H ;
Pachnis, V .
NATURE, 1996, 381 (6585) :789-793
[8]   POINT MUTATION WITHIN THE TYROSINE KINASE DOMAIN OF THE RET PROTOONCOGENE IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B AND RELATED SPORADIC TUMORS [J].
ENG, C ;
SMITH, DP ;
MULLIGAN, LM ;
NAGAI, MA ;
HEALEY, CS ;
PONDER, MA ;
GARDNER, E ;
SCHEUMANN, GFW ;
JACKSON, CE ;
TUNNACLIFFE, A ;
PONDER, BAJ .
HUMAN MOLECULAR GENETICS, 1994, 3 (02) :237-241
[9]  
ENG C, 1995, ONCOGENE, V10, P509
[10]   The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 - International RET mutation consortium analysis [J].
Eng, C ;
Clayton, D ;
Schuffenecker, I ;
Lenoir, G ;
Cote, G ;
Gagel, RF ;
vanAmstel, HKP ;
Lips, CJM ;
Nishisho, I ;
Takai, SI ;
Marsh, DJ ;
Robinson, BG ;
FrankRaue, K ;
Raue, F ;
Xue, FY ;
Noll, WW ;
Romei, C ;
Pacini, F ;
Fink, M ;
Niederle, B ;
Zedenius, J ;
Nordenskjold, M ;
Komminoth, P ;
Hendy, GN ;
Gharib, H ;
Thibodeau, SN ;
Lacroix, A ;
Frilling, A ;
Ponder, BAJ ;
Mulligan, LM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (19) :1575-1579